8-K · latest 10
What BD's 8-K filings say
- SEC EDGAR
8-K
Filed · 3 signals
BDX President of Medical & BioPharma segments to retire; search for successor underway
The retirement of Michael D. Garrison, President of the Medical Essentials segment, triggers a search for a new leader.
BDX EVP Michael Garrison to retire, triggering leadership search and segment reorganization.
The BioPharma Systems segment will now report directly to the CEO, indicating increased executive oversight and potential strategic shifts.
- SEC EDGAR
8-K
Filed · 5 signals
BDX resumes shipment of ChloraPrep™ & PurPrep™ after voluntary ship hold due to quality concerns.
The company placed its ChloraPrep™ and PurPrep™ products on a ship hold in the U.S.
The company is responding to an FDA Warning Letter concerning its El Paso plant, which forced a temporary halt in product shipments and implementation of new testing protocols.
BDX addresses quality issues after FDA Warning Letter for its El Paso manufacturing facility.
The company was forced to implement additional final release testing for its ChloraPrep™ and PurPrep™ products due to an FDA Warning Letter.
BDX resumes product shipments after hold prompted by FDA Warning Letter
A voluntary ship hold on ChloraPrep™ and PurPrep™ was enacted due to an FDA Warning Letter at its El Paso manufacturing facility, indicating significant quality control and compliance challenges.
- SEC EDGAR
8-K
Filed · 3 signals
BDX subsidiary raises €600M in debt offering to refinance notes and fund corporate purposes.
Becton Dickinson has secured €600 million in long-term financing, extending its debt maturity profile.
$600M
€600M aggregate principal amount of 3.855% Notes due 2033 issued by a subsidiary.
3.855%
Interest rate on new €600M notes due 2033.
The Bank of New York Mellon Trust Company, N.A.Loyens & Loeff Luxembourg S.à r.l.Skadden, Arps, Slate, Meagher & Flom LLP
- SEC EDGAR
8-K
Filed · 2 signals
BDX raises €600M in new debt to refinance notes due June 2026.
The company is issuing new 3.855% notes due 2033 to repay existing 1.208% notes maturing on June 4, 2026.
$600M
€600M aggregate principal amount of new notes issued to refinance existing debt.
3.86%
Interest rate on new €600M notes due 2033.
Barclays Bank PLCBNP PARIBASGoldman Sachs & Co. LLCMorgan Stanley & Co. International plc
- SEC EDGAR
8-K
Filed · 3 signals
Vitor Roque appointed permanent EVP & CFO, effective May 7, 2026.
$3M
Annual equity compensation award target value for new CFO
95%
Annual target bonus as a percentage of base salary for new CFO
- SEC EDGAR
8-K
Filed · 3 signals
Earlier 8-K filings
Showing 10 of 29 filing signals. The Signal API returns all of them.
Get them with one API callSignal API · MCP
Track BD with the Signal API
One POST /v1/companies/enrich call with bd.com returns BD 8-K signals (sec-8k), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"bd.com","signal_types":["sec-8k"],"limit":20}'Same industry
8-K at related companies
Questions about BD 8-K
When did BD file its latest 8-K?
What did BD disclose in its latest 8-K?
Where can I read BD's 8-K filing?
Source. Current reports (Form 8-K) filed with the SEC. Every card links to the filing on EDGAR.
Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.
Data as of .